MedTrace Logo

A Safety and Efficacy Study to Evaluate Rosacea

NCT03883945 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2024-12-17

No results posted yet for this study

Summary

To evaluate the safety, efficacy, and pharmacokinetic profile of ascending concentrations of the study medication compared with vehicle in subjects with rosacea.

Conditions

  • Papulopustular Rosacea

Interventions

DRUG

AIV001

intradermal injection

DRUG

Vehicle

intradermal injection

Sponsors & Collaborators

  • AiViva BioPharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Mitchell Goldman, MD · West Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-31
Primary Completion
2022-07-31
Completion
2022-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03883945 on ClinicalTrials.gov